Trevi Therapeutics (TRVI) director receives 35K nonstatutory option grant
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Trevi Therapeutics, Inc. director David P. Meeker received a grant of a nonstatutory stock option covering 35,000 shares of common stock. The option has an exercise price of $13.45 per share and expires on June 2, 2036.
The option is scheduled to fully vest on the earlier of the first anniversary of the June 3, 2026 grant date or the next annual stockholder meeting held after that date, subject to his continued service as a director, employee or consultant. Following this grant, Meeker holds 35,000 derivative securities directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Meeker David P
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Nonstatutory Stock Option (right to buy) | 35,000 | $0.00 | -- |
Holdings After Transaction:
Nonstatutory Stock Option (right to buy) — 35,000 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Option grant size: 35,000 options
Exercise price: $13.45 per share
Expiration date: June 2, 2036
+3 more
6 metrics
Option grant size
35,000 options
Nonstatutory stock option awarded June 3, 2026
Exercise price
$13.45 per share
Strike price of nonstatutory stock option
Expiration date
June 2, 2036
Option term end date
Underlying shares
35,000 shares
Common stock underlying the option
Post-grant derivative holdings
35,000 options
Total derivative securities held directly after grant
Vesting condition
Earlier of 1-year anniversary or next annual meeting
Subject to continued service with issuer
Key Terms
Nonstatutory Stock Option, grant/award acquisition, exercise price, expiration date, +1 more
5 terms
Nonstatutory Stock Option financial
"Nonstatutory Stock Option (right to buy)"
A nonstatutory stock option (also called a non-qualified stock option) is an employee or contractor right to buy company shares at a set price that does not qualify for special tax treatment. When exercised, the difference between the market price and the set price is treated as ordinary income for the recipient and usually triggers payroll tax and withholding. For investors, these options matter because they create potential share dilution, affect reported compensation costs, and influence the timing of when new shares enter the market—similar to a coupon that lets someone buy stock at a discount but results in an immediate tax bill.
grant/award acquisition financial
"transaction_action: grant/award acquisition"
exercise price financial
"conversion_or_exercise_price: 13.4500"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-06-02T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vest financial
"This option is scheduled to fully vest on the earlier of"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
FAQ
What insider transaction did Trevi Therapeutics (TRVI) report for David P. Meeker?
Trevi Therapeutics reported a grant of 35,000 nonstatutory stock options to director David P. Meeker. These options give him the right to buy common shares at a fixed price as part of his compensation, not through an open-market purchase or sale.
What is the exercise price of David Meeker’s Trevi Therapeutics stock options?
David Meeker’s nonstatutory stock option has an exercise price of $13.45 per share. This fixed price determines what he must pay per share if he chooses to exercise the option and acquire Trevi Therapeutics common stock in the future.
When do David Meeker’s Trevi Therapeutics stock options vest?
David Meeker’s option is scheduled to fully vest on the earlier of the first anniversary of the June 3, 2026 grant date or the next annual stockholder meeting. Vesting is conditioned on his continued service as a director, employee or consultant.
When do David Meeker’s Trevi Therapeutics stock options expire?
The nonstatutory stock option granted to David Meeker expires on June 2, 2036. After that expiration date, he can no longer exercise the option to buy Trevi Therapeutics common shares at the $13.45 per share exercise price.
Is David Meeker’s Trevi Therapeutics Form 4 transaction a market buy or sell?
The Form 4 transaction is a grant of a nonstatutory stock option, classified as an acquisition. It is a compensation-related award rather than an open-market purchase or sale, and it does not involve a cash transaction in the company’s stock.